Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Analyst Rating Guide

News

Back

Biora Therapeutics Announces Clinical Trial Results For BT-600

Author: Benzinga Newsdesk | July 01, 2024 08:01am

Drug-device combination leverages Biora's NaviCap™ platform to deliver tofacitinib directly to colonic tissue as a potential treatment for ulcerative colitis

BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform's ability to deliver therapeutics directly to the colon

Drug absorption in colonic tissue extended to distal colon, suggesting pan-colonic delivery

Company to host virtual event with key opinion leaders on July 17

Posted In: BIOR

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)

07/05/2024 Altimmune, Inc. (ALT)

07/09/2024 Li Auto Inc. (LI)

07/12/2024 Inari Medical, Inc. (NARI)

07/12/2024 Sprout Social, Inc. (SPT)

07/15/2024 UnitedHealth Group Inc. (UNH)

07/16/2024 Teladoc Health, Inc. (TDOC)

07/16/2024 Vestis Corporation (VSTS)

07/22/2024 Cambium Networks Corporation (CMBM)

07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)